Can we taper steroids without Flare-Ups? new study aims to find out
NCT ID NCT06072768
First seen Nov 19, 2025
Summary
This study is testing two different ways to slowly reduce the dose of the steroid prednisone in people with rheumatoid arthritis. One group will taper over 15 days, the other over 150 days. Researchers want to see who develops symptoms or flare-ups during the taper, and why. The goal is to learn how to personalize steroid tapering to minimize side effects and keep arthritis under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
VA Ann Arbor Healthcare System, Ann Arbor, MI
RECRUITINGAnn Arbor, Michigan, 48105-2303, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
prednisone
What this could lead to
If successful, this could help doctors personalize steroid tapering plans for rheumatoid arthritis patients, reducing side effects while maintaining disease control.
What could go wrong
This is an early-phase study with only 200 participants, so results may not apply to everyone. The focus is on understanding responses, not on proving a new treatment works.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.